Compare NAMS & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAMS | DAVE |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | N/A | N/A |
| Metric | NAMS | DAVE |
|---|---|---|
| Price | $34.68 | $196.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $45.80 | ★ $282.17 |
| AVG Volume (30 Days) | ★ 1.1M | 449.6K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 224.46 |
| EPS | N/A | ★ 10.12 |
| Revenue | $35,243,000.00 | ★ $491,301,000.00 |
| Revenue This Year | N/A | $56.88 |
| Revenue Next Year | N/A | $18.07 |
| P/E Ratio | ★ N/A | $19.53 |
| Revenue Growth | 4.91 | ★ 53.84 |
| 52 Week Low | $14.06 | $65.46 |
| 52 Week High | $42.00 | $286.45 |
| Indicator | NAMS | DAVE |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 45.24 |
| Support Level | $34.59 | $190.05 |
| Resistance Level | $37.41 | $207.46 |
| Average True Range (ATR) | 1.79 | 11.46 |
| MACD | -0.40 | -0.23 |
| Stochastic Oscillator | 1.97 | 25.30 |
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.